🇺🇸 FDA
Patent

US 7501415

Selective inhibitors of ERK protein kinase and uses thereof

granted A61PA61P1/16A61P11/00

Quick answer

US patent 7501415 (Selective inhibitors of ERK protein kinase and uses thereof) held by Vertex Pharmaceuticals Incorporated expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P1/16, A61P11/00, A61P17/06, A61P25/00